2hats
Dust.
Moderna have commenced trials of their next COVID-19 vaccine, mRNA-1283, which can potentially be shipped and stored at standard refrigerator temperatures. This is a phase I study evaluating doses at 10 µg, 30 µg, and 100 µg, as a 2-dose series, 28 days apart, and a single dose at 100 µg to compare with the current, approved, two dose regimen of 100 µg of mRNA-1273.
First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine | Moderna, Inc.
mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 15, 2021-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA)
investors.modernatx.com
Last edited: